Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Keystone, E.

Refine Results

Resource Type

Availability

Creation Date

Show more

Author

Show more

Language

Search results

  • RSS Feed
(25 - 39 of 39)

Pages

Disconnect Between Disease Activity and Joint Space Narrowing for Patients with Early Ra Treated with Adalimumab plus Methotrexate but not Methotrexate Alone: Case for Anti-Tnf Cartilage Protection
Time to and Level of Initial DAS28 Change With Certolizumab Pegol Predicts the Likelihood of Having Low Disease Activity at Years 1 and 2 in Patients With Rheumatoid Arthritis
Assessing the Rate of Serious Infections in Rheumatoid Arthritis (RA) Patients who Receive Other Biologic Therapies after Discontinuing Rituximab (RTX)
Joint Space Narrowing has a Stronger Impact on Physical Function Than Joint Erosion: Results From 8-year Longitudinal Analyses
PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY AT 52 WEEKS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL DEPENDS ON TIME TO AND LEVEL OF INITIAL RESPONSE
JOINT SPACE NARROWING HAS A STRONGER IMPACT ON PHYSICAL FUNCTION THAN JOINT EROSION: RESULTS FROM EIGHT YEAR LONGITUDINAL ANALYSES
SAFETY OF SUBSEQUENT BIOLOGIC THERAPY IN RA PATIENTS WHO DISCONTINUED RITUXIMAB
DISCONNECT BETWEEN DISEASE ACTIVITY AND JOINT SPACE NARROWING FOR PATIENTS WITH EARLY RA TREATED WITH ADALIMUMAB PLUS METHOTREXATE BUT NOT METHOTREXATE ALONE: CASE FOR ANTI-TNF CARTILAGE PROTECTION
GOLIMUMAB AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS: RESULTS OF GO-BEFORE AND GO-FORWARD STUDIES
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
Improvements in Radiographic, Clinical, and Functional Outcomes for Patients With Rheumatoid Arthritis Treated With Adalimumah Plus Methotrexate Through 8 Years
Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response
The Efficacy of Certolizumab Pegol Added to Methotrexate is Sustained Over 2 Years in the Treatment of Rheumatoid Arthritis
Incremental Benefit of Open-Label Certolizumab Pegol plus MTX in Rheumatoid Arthritis (RA) Patients Following Double-Blind Placebo plus IVITX Treatment Out to 2 Years

Pages